Lymphoma & Plasma Cell Disorders
News
Cancer patients’ complaints about care
A new study suggests cancer patients may be more concerned with the human aspects of care than the technical ones. Researchers studied complaints...
News
EC expands approval of obinutuzumab in FL
The European Commission (EC) has expanded the marketing authorization for obinutuzumab (Gazyvaro). The drug is now approved for use in combination...
News
FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma
The Food and Drug Administration has granted accelerated approval to copanlisib (Aliqopa) for the treatment of adults with relapsed follicular...
Conference Coverage
New antibodies, drugs for refractory and relapsed myeloma are effective in patients over 65
MADRID – Patients with refractory/relapsed multiple myeloma had similar rates of progression-free survival whether they were younger than age 65...
News
Team creates guidelines on CAR T-cell-related toxicity
Researchers say they have created guidelines for managing the unique toxicities associated with chimeric antigen receptor (CAR) T-cell therapy....
News
Trials of atezolizumab placed on partial hold
Roche has announced a partial clinical hold on 2 trials of the anti-PD-L1 antibody atezolizumab (Tecentriq). One is a phase 1b/2 study (...
News
Application for pegfilgrastim biosimilar withdrawn
Mylan S.A.S.
From the Journals
In Hodgkin lymphoma, HAPLO transplant outcomes match those of conventional transplants
HAPLO transplants may prove a better option than HLA-matched unrelated donor transplants.
News
FDA approves drug to treat relapsed FL
The US Food and Drug Administration (FDA) has granted accelerated approval to copanlisib (Aliqopa), an intravenous PI3K inhibitor developed by...
News
Immune status linked to outcomes of CAR T-cell therapy
MAINZ/FRANKFURT, GERMANY—Outcomes of treatment with a third-generation chimeric antigen receptor (CAR) T-cell therapy are associated with a...
Conference Coverage
Survey reveals lack of specialized care for AYAs with cancer
MADRID—New research indicates there is a lack of specialized care in Europe for adolescents and young adults (AYAs) with cancer. In a survey of...